Publications by authors named "I Ahronowitz"
Article Synopsis
- Pityriasis rubra pilaris (PRP) is a rare skin condition marked by red-orange patches and thickened skin, posing challenges in treatment.
- Recent advancements in targeted biologic therapies, particularly ixekizumab, an interleukin-17 inhibitor, have shown promise in managing PRP with minimal side effects.
- A patient treated with ixekizumab experienced complications including Kaposi's varicelliform eruption and a pseudomonal superinfection three months post-treatment.
Background: Immunocompromised patients, including those with human immunodeficiency virus (HIV), have been observed to have verrucae that are more extensive and treatment-resistant compared to those in immunocompetent patients. However, there is a critical lack of data in the current literature on the characteristics of verruca vulgaris in individuals with HIV.
Methods: This retrospective chart review included a cohort of HIV-positive individuals and a control group of immunocompetent individuals presenting to an outpatient, county hospital-based dermatology clinic for evaluation of verruca vulgaris between the years of 2016 and 2018.